scholarly journals Trastuzumab induced radiation recall dermatitis: an interesting case

2018 ◽  
Vol 7 (12) ◽  
pp. 2465
Author(s):  
Anupama C. ◽  
Anuradha H. V. ◽  
Vinayak V. Maka
Keyword(s):  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Radical Mastectomy ◽  
Left Breast ◽  
Interesting Case ◽  
Axillary Lymph ◽  
Radiation Recall ◽  
Skin Reactions ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Radiation recall dermatitis (RRD) is the appearance of skin reactions in previously irradiated skin which is triggered by the administration of certain drugs. Surgery, chemotherapy, and radiotherapy are the mainstay of treatment in breast cancer. RRD induced by trastuzumab has been rarely reported in India. This is a case report of a 56-year-old woman presented to the medical oncology outpatient department of our hospital with breast lump, and she was diagnosed to have human epidermal growth factor receptor 2 (HER-2/neu) positive invasive ductal carcinoma of left breast of stage T2N3cM0. She was treated with neoadjuvant chemotherapy, and she underwent modified radical mastectomy with axillary lymph node dissection. The treating oncologist was planned to start on adjuvant chemotherapy with injection trastuzumab for every four weeks, for 15 cycles. Patient received first dose of injection trastuzumab (450 mg) intravenously in the right (contralateral) arm and developed painful, swollen, erythematous blisters, and maculopapular rashes following the sharp linear borders of her previous radiation fields. She was reviewed by the medical oncologist and diagnosed as a rare case of RRD and treated with topical betamethasone cream. Causality assessment for RRD to trastuzumab was done using Naranjo and WHO-UMC scale and found to be in the category of probable and probable/ likely respectively.

scholarly journals Concomitant Radiation Recall Dermatitis and Organizing Pneumonia following Breast Radiotherapy: A Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 875-882 ◽  
Author(s):  
I-Chia Liu ◽  
Fantine Giap ◽  
Raymond B. Mailhot-Vega ◽  
Julie A. Bradley ◽  
Nancy P. Mendenhall ◽  
...  
Keyword(s):  
Lymph Node ◽  
Ductal Carcinoma ◽  
Rare Complication ◽  
Clinical Stage ◽  
Axillary Lymph ◽  
Organizing Pneumonia ◽  
Radiation Recall ◽  
Autoimmune Reaction ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Purpose: Radiation recall dermatitis (RRD) is a rare complication that occurs after completion of radiation therapy (RT) and initiation of a precipitating agent, most commonly chemotherapeutic medications. Various theories attempt to explain the mechanism, including activation of the body’s inflammatory pathways through nonimmune activation. Likewise, radiation-induced organizing pneumonia (RIOP) is an infrequent but potentially life-threatening complication of RT that, while not fully understood, is suspected to be partly an autoimmune reaction. Patient: We present the case of a 71-year-old female with a history of type 2 diabetes mellitus, hypothyroidism, interstitial cystitis, and osteoarthritis who presented with clinical stage T1N0M0 ER+/PR–/HER2– invasive ductal carcinoma of the lower outer quadrant of the left breast, for which she underwent left segmental mastectomy and sentinel lymph node biopsy followed by completion axillary lymph node dissection. Her final pathologic stage was T1N1M0. Result: The patient developed RRD and later RIOP following receipt of radiation and chemotherapy, which resolved with steroid administration. Conclusions: The rarity of both RRD and RIOP occurring in a patient, as in our case, suggests a shared pathophysiology behind these two complications. As both reactions involve some degree of inflammation and respond to corticosteroids, it seems likely that the etiologies of RRD and RIOP lie within the inflammatory pathway. However, further investigation should evaluate the frequency, duration, and triggering of concomitant RRD and RIOP.

Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report

Immunotherapy ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 123-130 ◽  
Author(s):  
Cole Billena ◽  
Shilpa Padia ◽  
Bridget O’Brien ◽  
Jeanna Knoble ◽  
Abhay Gokhale ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Spinal Metastasis ◽  
Radical Mastectomy ◽  
Multidisciplinary Teams ◽  
Adjuvant Radiation ◽  
Radiation Recall ◽  
Stage Iv Breast Cancer ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Radiation recall dermatitis (RRD) is an uncommon dermatologic reaction provoked notably by chemotherapy in an area of skin irradiated weeks to years prior. We report a case of RRD with nivolumab in a woman with breast cancer. The patient was diagnosed with invasive ductal carcinoma of the left breast with an isolated spinal metastasis approached in an oligometastatic fashion with neoadjuvant chemotherapy, modified radical mastectomy and adjuvant radiotherapy. Unfortunately, after progression of bony metastases treated with radiotherapy, the patient received nivolumab and subsequently developed a rash corresponding to the adjuvant radiation field. This case highlights the unpredictable nature and characteristic rash of RRD. It is an important differential diagnosis for multidisciplinary teams who also see chemotherapy-induced dermatitis and immune-related adverse events.

Bullous pemphigoid development during the course of breast cancer: a radiation induced or a radiation recall dermatitis?

2020 ◽  
pp. 1-3
Author(s):  
Mouna Ben Rejeb ◽  
Rim Moujahed ◽  
Alia Zehani ◽  
Lotfi Kochbati
Keyword(s):  
Breast Cancer ◽  
Bullous Pemphigoid ◽  
Radical Mastectomy ◽  
Trigger Factor ◽  
Radiation Recall ◽  
Adjuvant Trastuzumab ◽  
Oral Corticosteroids ◽  
Radiation Induced ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Abstract Background: Bullous pemphigoid (BP) is the most common autoimmune bullous disease, which is usually seen in older ages. Rarely, radiotherapy (RT) has been reported as a localised trigger factor for BP. Case: We present a case of a 64-year-old woman who underwent radical mastectomy and radiation therapy for breast cancer. Two months after the completion of RT with adjuvant Trastuzumab, a BP eruption developed in the irradiated area, spreading thereafter to other skin areas. The patient was treated with oral corticosteroids and the lesions evolved favourably. Conclusion: This case demonstrates a relatively benign skin reaction that could develop during the course of cancer treatment, which required co-management by oncologists, pathologists and dermatologists.

scholarly journals A Case Report of Triple-Positive Micropapillary Carcinoma of the Male Breast

Breast Care ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. 192-194 ◽  
Author(s):  
Jamila Shuja ◽  
Iftikhar Ahmad ◽  
Sidra Arshad ◽  
Hina Manzoor ◽  
Shahwali Kakar ◽  
...  
Keyword(s):  
Case Report ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Radical Mastectomy ◽  
Multimodality Treatment ◽  
Lymph Node Involvement ◽  
Male Breast ◽  
Axillary Lymph ◽  
Micropapillary Carcinoma ◽  
Disease Case

Background: Micropapillary carcinoma (MPC), a morphologically distinct subtype of invasive ductal carcinoma, of the male breast is an exceedingly uncommon disease. Case Report: Herein, we report a case of triple-positive MPC of the male breast with axillary lymph node involvement and no recurrence for over 2 years. Specifically, a 60-year-old male patient presented with a hard, elastic, and well-defined painless mass in the right breast. The patient underwent unilateral (right) modified radical mastectomy with axillary clearance. Histopathology revealed MPC grade 3 and metastasis in 16/16 lymph nodes. Hormone receptor analysis demonstrated strong positivity (total score 08) for estrogen/progesterone receptors and overexpression (score 3+) of human epidermal growth factor receptor 2. The patient received adjuvant chemotherapy (6 courses of CAF: cyclophosphamide, doxorubicin, and 5-fluorouracil), radiation, and tamoxifen. The patient has remained disease-free for over 2 years. Conclusion: This study demonstrates that triple-positive MPC of the male breast as a rare malignancy appears to respond promisingly to multimodality treatment.

scholarly journals Synchronous breast and colon cancer: the importance of multidisciplinary team cancer meetings

2019 ◽  
Vol 12 (12) ◽  
pp. e232680
Author(s):  
Hussain Adnan Abdulla ◽  
Raed Almarzooq ◽  
Amal Alrayes
Keyword(s):  
Colon Cancer ◽  
Multidisciplinary Team ◽  
Ductal Carcinoma ◽  
Histopathological Examination ◽  
Radical Mastectomy ◽  
Right Hemicolectomy ◽  
Left Breast ◽  
Axillary Lymph Node Metastasis ◽  
Axillary Lymph ◽  
Ascending Colon

A 58-year-old female patient presented with left breast lump. Mammography and ultrasonography were performed, which reported lesions suspicious of malignancy in the left breast and axilla. Core biopsy of the lesions revealed invasive ductal carcinoma with axillary lymph node metastasis. Staging CT scan (thorax, abdomen and pelvis) identified a coexisting neoplasm in the ascending colon. Colonoscopy was performed and the tumour in the ascending colon was biopsied. Histopathological examination revealed adenocarcinoma. In the multidisciplinary team cancer meeting, it was decided to treat the breast cancer first and then the colon cancer, followed by adjuvant chemotherapy. In the first operation, left modified radical mastectomy was performed. Two weeks after her initial operation, the patient underwent laparoscopic right hemicolectomy. Postoperatively, the patient did not develop any complications and was referred to oncology for chemotherapy.

Recurrent radiation recall dermatitis 40 years after radiation therapy for breast cancer

2021 ◽  
Author(s):  
Muhammad F. Jamaluddin ◽  
Aswin G. Abraham ◽  
Geetha Menon ◽  
Thomas Nakatsui ◽  
Wilson Roa
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Radiation Recall ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

A case of potential radiation recall dermatitis induced by chemotherapy, following low-dose total-skin electron beam therapy

2019 ◽  
Vol 29 (6) ◽  
pp. 671-672 ◽  
Author(s):  
Carl Lamoureux ◽  
Emilie Gerard ◽  
Nora Ouhabrache ◽  
Feyrouz Toukal ◽  
Anne Pham-Ledard ◽  
...  
Keyword(s):  
Electron Beam ◽  
Low Dose ◽  
Radiation Recall ◽  
Electron Beam Therapy ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Radiation recall dermatitis and pneumonitis induced by trastuzumab (Herceptin®)

2013 ◽  
Vol 53 (3) ◽  
pp. e159-e160 ◽  
Author(s):  
Hae Eul Lee ◽  
Nam Ji Jeong ◽  
Young Lee ◽  
Young Joon Seo ◽  
Chang Deok Kim ◽  
...  
Keyword(s):  
Radiation Recall ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

Radiation Recall Dermatitis Secondary to Dactinomycin

2016 ◽  
Vol 33 (5) ◽  
pp. e278-e279 ◽  
Author(s):  
Brea Prindaville ◽  
Kimberly A. Horii ◽  
Kristi M. Canty
Keyword(s):  
Radiation Recall ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis

scholarly journals Radiation Recall Dermatitis in Patients Treated with Sorafenib

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Keyur Mehta ◽  
Andreas Kaubisch ◽  
Justin Tang ◽  
Aneesh Pirlamarla ◽  
Shalom Kalnicki
Keyword(s):  
Chemotherapeutic Agent ◽  
Review Of The Literature ◽  
Radiation Recall ◽  
Case Presentation ◽  
Palliative Radiation Therapy ◽  
Metastatic Hepatocellular Carcinoma ◽  
Radiation Recall Dermatitis ◽  
Recall Dermatitis ◽  
The Right ◽  
Carcinoma Lesion

Introduction. Radiation recall dermatitis (RRD) is a phenomenon that occurs in previously irradiated areas shortly after administration of a chemotherapeutic agent. As the use of sorafenib expands, the incidence of radiation recall dermatitis induced by sorafenib will likely increase. Here, we report on a patient who developed RRD and describe his clinical characteristics along with a review of the literature. Case Presentation. Our patient was treated with palliative radiation therapy (RT) to a painful metastatic hepatocellular carcinoma lesion in the right forearm. He completed his radiation course with grade 1 dermatitis, which had resolved by the time he was started on sorafenib 400 mg twice daily 7 days afterwards. On the 21st day after RT, he presented with desquamation and erythema in the previously irradiated area of the right forearm, consistent with RRD. The sorafenib was discontinued and his symptoms subsequently resolved with conservative topical management. Conclusions. Although the pathophysiologic mechanism of sorafenib-related radiation recall dermatitis remains to be investigated, practitioners should be aware of its presence and management in order to improve clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document